MARKET NEWS

 

Catalent Launches Delayed/Enteric-Release Softgel for Pharmaceutical & Nutraceutical Applications
VBL Therapeutics Announces Additional New European Patent
First Patient Dosed in Phase 2 Trial to Treat Complications in COVID-19
PepTC Vaccines Publishes Positive Preclinical Results for COVID-19 Peptide Vaccine
Castle Creek Biosciences Treats First Patient in Phase 1/2 Gene Therapy Trial
Beroni Group Announces Successful Completion of SARS-CoV-2 Pseudovirus Neutralization Assay for Treatment of COVID-19

  FEATURED EDITORIAL

 

  COMPANY PROFILE

Element is your partner of choice. Through our global network of laboratories we offer a broad spectrum of pharmaceutical development and testing services. Our core services include analytical method development; batch release; API and raw material analysis; organic and elemental impurities determination; plastics and polymer testing; analytical testing in support of clinical trials, and stability studies. Element is a leader in providing risk-based extractables and leachables programs. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Lonza Significantly Expands Its Capsule Manufacturing Capacity

Lonza Significantly Expands Its Capsule Manufacturing Capacity

Lonza recently announced a $93-million investment in its Capsules and Health Ingredients (CHI) Division, a dosage form delivery partner to the biopharma and health nutrition industry…..

Quantum Genomics Enters Exclusive Licensing & Collaboration Agreement With Qilu Pharmaceutical

Quantum Genomics Enters Exclusive Licensing & Collaboration Agreement With Qilu Pharmaceutical

Quantum Genomics recently announced it has entered into an exclusive licensing and collaboration agreement with Qilu Pharmaceutical to develop and commercialize….

NGM Expands Oncology Portfolio With First Immuno-Oncology Development Candidate

NGM Expands Oncology Portfolio With First Immuno-Oncology Development Candidate

NGM Biopharmaceuticals, Inc. recently announced the expansion of its oncology portfolio with its first immuno-oncology development candidate….

BrainStorm Cell Therapeutics & Catalent Announce Manufacturing Partnership 

BrainStorm Cell Therapeutics & Catalent Announce Manufacturing Partnership 

Catalent and BrainStorm Cell Therapeutics Inc. recently announced an agreement for the manufacture of NurOwn, BrainStorm’s autologous cellular therapy being investigated for the treatment of….

WEBINAR ALERT: Stability Testing as Quality Control Measure: Optimizing the Process Throughout the Product Lifecycle

WEBINAR ALERT: Stability Testing as Quality Control Measure: Optimizing the Process Throughout the Product Lifecycle

Assessing a compound’s stability is a complex and lengthy process with objectives varying by the development phase…..